OA11221A - Quinoline and quinoxaline compounds which inhibit platelet-derived growt factor and/or p561ck tyrosine kinases - Google Patents

Quinoline and quinoxaline compounds which inhibit platelet-derived growt factor and/or p561ck tyrosine kinases Download PDF

Info

Publication number
OA11221A
OA11221A OA9900261A OA9900261A OA11221A OA 11221 A OA11221 A OA 11221A OA 9900261 A OA9900261 A OA 9900261A OA 9900261 A OA9900261 A OA 9900261A OA 11221 A OA11221 A OA 11221A
Authority
OA
OAPI
Prior art keywords
compound
optionally substituted
ylamino
cyclohexanol
dimethoxyquinoxalin
Prior art date
Application number
OA9900261A
Other languages
English (en)
Inventor
Wei He
Michael R Myers
Alfred P Spada
Original Assignee
Rhone Poulenc Rorer Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Pharma filed Critical Rhone Poulenc Rorer Pharma
Publication of OA11221A publication Critical patent/OA11221A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
    • C07D241/52—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
    • C07D241/54—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
OA9900261A 1997-05-28 1999-11-29 Quinoline and quinoxaline compounds which inhibit platelet-derived growt factor and/or p561ck tyrosine kinases OA11221A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86445597A 1997-05-28 1997-05-28
US97261497A 1997-11-18 1997-11-18

Publications (1)

Publication Number Publication Date
OA11221A true OA11221A (en) 2003-07-16

Family

ID=27127839

Family Applications (3)

Application Number Title Priority Date Filing Date
OA9900261A OA11221A (en) 1997-05-28 1999-11-29 Quinoline and quinoxaline compounds which inhibit platelet-derived growt factor and/or p561ck tyrosine kinases
OA9900260A OA11264A (en) 1997-05-28 1999-11-29 Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p561ck tyrosine kinases
OA9900262A OA11222A (en) 1997-05-28 1999-11-29 Quinoline and quinoxaline compounds which inhibit platelet-derived growt factor and/or p561 ck tyrosine kinases

Family Applications After (2)

Application Number Title Priority Date Filing Date
OA9900260A OA11264A (en) 1997-05-28 1999-11-29 Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p561ck tyrosine kinases
OA9900262A OA11222A (en) 1997-05-28 1999-11-29 Quinoline and quinoxaline compounds which inhibit platelet-derived growt factor and/or p561 ck tyrosine kinases

Country Status (26)

Country Link
EP (3) EP1001946B1 (no)
JP (3) JP2002513417A (no)
KR (2) KR100425638B1 (no)
CN (3) CN1140516C (no)
AP (3) AP1444A (no)
AT (3) ATE493389T1 (no)
AU (3) AU742739B2 (no)
BG (3) BG64419B1 (no)
BR (3) BR9809172A (no)
CA (3) CA2291774A1 (no)
CZ (3) CZ296845B6 (no)
DE (3) DE69828607T2 (no)
DK (1) DK0991628T3 (no)
EA (4) EA004103B1 (no)
ES (1) ES2235331T3 (no)
HK (1) HK1028042A1 (no)
HU (2) HUP0004807A3 (no)
IL (3) IL133007A (no)
NO (3) NO323720B1 (no)
OA (3) OA11221A (no)
PL (3) PL194670B1 (no)
PT (1) PT991628E (no)
SI (1) SI0991628T1 (no)
SK (4) SK158099A3 (no)
UA (1) UA57790C2 (no)
WO (3) WO1998054158A1 (no)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK158099A3 (en) * 1997-05-28 2000-06-12 Rhone Poulenc Rorer Pharma Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6159978A (en) * 1997-05-28 2000-12-12 Aventis Pharmaceuticals Product, Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6180632B1 (en) 1997-05-28 2001-01-30 Aventis Pharmaceuticals Products Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6245760B1 (en) * 1997-05-28 2001-06-12 Aventis Pharmaceuticals Products, Inc Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
GB9904103D0 (en) 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
US6506769B2 (en) 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
US7101869B2 (en) 1999-11-30 2006-09-05 Pfizer Inc. 2,4-diaminopyrimidine compounds useful as immunosuppressants
US6489328B2 (en) 2000-08-11 2002-12-03 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
DK1497266T3 (da) 2002-03-27 2008-10-06 Glaxo Group Ltd Quinolinderivater og deres anvendelse som 5HT6-ligander
DE10237423A1 (de) * 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
TW200523253A (en) 2003-07-22 2005-07-16 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
UA85698C2 (ru) 2004-01-16 2009-02-25 Уайет Хинолиновые промежуточные соединения для синтеза ингибиторов рецепторной тирозинкиназы и способ их получения
CL2008001356A1 (es) 2007-05-10 2008-11-14 Smithkline Beecham Corp Compuestos derivados de quinoxalina, inhibidores de la pi3 quinasa _(p13ka, pi3ko, pi3b y/o pi3ky); composicion farmaceutica; uso para tratar un trastorno autoinmune, enfermedad inflamatoria, cardiovascular, neurodegerativa, alergia, asma, enfermedad renal, cancer, rechazo de transplante, lesiones pulmonares.
US9084742B2 (en) 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
EP2241557A1 (de) 2009-04-02 2010-10-20 Æterna Zentaris GmbH Chinoxalin-Derivate und deren Anwendung zur Behandlung gutartiger und bösartiger Tumorerkrankungen
CA2772790C (en) 2009-09-04 2017-06-27 Benjamin Bader Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
CN101823998B (zh) * 2010-05-05 2015-03-25 江苏利田科技股份有限公司 一种反应器耦合模拟移动床乙氧基喹啉清洁生产工艺
PT2624695E (pt) 2010-10-08 2015-12-01 Nivalis Therapeutics Inc Novos compostos de quinolina substituídos como inibidores de s-nitrosoglutationa redutase
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
JP5990187B2 (ja) 2010-12-16 2016-09-07 ニヴァリス・セラピューティクス・インコーポレーテッド Ｓ−ニトロソグルタチオン還元酵素阻害薬としての新規な置換二環芳香族化合物
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
EP2825540B1 (en) 2012-03-14 2016-09-14 Bayer Intellectual Property GmbH Substituted imidazopyridazines
US9296701B2 (en) 2012-04-24 2016-03-29 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
ME03300B (me) 2012-06-13 2019-07-20 Incyte Holdings Corp Supsтituisana triciklična jedinjenja као inhibiтori fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
DK3527563T3 (da) 2013-03-12 2021-12-06 Vertex Pharma Dna-pk-inhibitorer
ME03015B (me) 2013-04-19 2018-10-20 Incyte Holdings Corp Biciklični heterocikli kao fgfr inhibitori
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
MX2015017119A (es) 2013-06-11 2016-04-06 Bayer Pharma AG Derivados de prodroga de triazolpiridinas sustituidas.
CN105814036B (zh) 2013-10-17 2018-10-26 沃泰克斯药物股份有限公司 作为dna-pk抑制剂的共晶
SI3122358T1 (sl) 2014-03-26 2021-04-30 Astex Therapeutics Ltd. Kombinacije FGFR- in CMET-inhibitorjev za zdravljenje raka
WO2015144808A1 (en) 2014-03-26 2015-10-01 Astex Therapeutics Ltd Combinations of an fgfr inhibitor and an igf1r inhibitor
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA51229A (fr) 2015-02-20 2021-03-24 Incyte Corp Hétérocycles bicycliques utilisés comme inhibiteurs des fgfr
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
AU2016291673A1 (en) 2015-07-15 2018-01-25 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
US10399946B2 (en) 2015-09-10 2019-09-03 Laurel Therapeutics Ltd. Solid forms of an S-Nitrosoglutathione reductase inhibitor
CN108026095B (zh) 2015-09-23 2021-07-27 詹森药业有限公司 新化合物
KR20180052631A (ko) 2015-09-23 2018-05-18 얀센 파마슈티카 엔.브이. 비-헤테로아릴 치환된 1,4-벤조디아제핀 및 암의 치료를 위한 이의 용도
CA3038657A1 (en) 2016-09-27 2018-04-05 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
MX2020011639A (es) 2018-05-04 2021-02-15 Incyte Corp Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr).
IL312465A (en) 2018-05-04 2024-06-01 Incyte Corp FGFR inhibitor solid forms and processes for their preparation
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4045151A1 (en) 2019-10-14 2022-08-24 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
MX2022006691A (es) 2019-12-04 2022-09-19 Incyte Corp Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
TW202313611A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1288436C (en) * 1983-07-22 1991-09-03 David Paul Hesson Phenylquinolinecarboxylic acids and derivatives as antitumor agents
US4888427A (en) * 1987-04-07 1989-12-19 University Of Florida Amino acids containing dihydropyridine ring systems for site-specific delivery of peptides to the brain
GB9004483D0 (en) 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
CA2102780C (en) 1991-05-10 2007-01-09 Alfred P. Spada Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
NO940245D0 (no) * 1993-01-28 1994-01-24 Takeda Chemical Industries Ltd Quinolin eller quinazolinderivater, deres fremstilling og anvendelse
DE4426373A1 (de) * 1994-07-26 1996-02-01 Bayer Ag 3-Substituierte Chinolin-5-carbonsäurederivate und Verfahren zu ihrer Herstellung
ATE338754T1 (de) * 1996-07-19 2006-09-15 Takeda Pharmaceutical Heterocyclische verbindungen, ihre herstellung und verwendung
CA2278244A1 (en) * 1997-01-21 1998-07-23 Nissan Chemical Industries, Ltd. Industrial antimicrobial/mildew-proofing agents, algicides and antifouling agents containing n-quinoxalylanilines
SK158099A3 (en) * 1997-05-28 2000-06-12 Rhone Poulenc Rorer Pharma Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases

Also Published As

Publication number Publication date
AP1444A (en) 2005-07-18
KR100440756B1 (ko) 2004-07-21
EP0991628B1 (en) 2005-01-12
HUP0002084A3 (en) 2000-12-28
SK157999A3 (en) 2000-06-12
PL195552B1 (pl) 2007-10-31
WO1998054157A1 (en) 1998-12-03
EP1001945A4 (en) 2000-07-26
NO995817D0 (no) 1999-11-26
HUP0004807A3 (en) 2001-12-28
DE69828607D1 (de) 2005-02-17
AP1362A (en) 2005-01-19
NO995819D0 (no) 1999-11-26
NO995818L (no) 1999-11-26
SK158099A3 (en) 2000-06-12
EA008136B1 (ru) 2007-04-27
HUP0004807A2 (hu) 2001-11-28
HK1028042A1 (en) 2001-02-02
WO1998054158A1 (en) 1998-12-03
CZ298521B6 (cs) 2007-10-24
AU747026B2 (en) 2002-05-09
BR9809172A (pt) 2000-08-01
EA199901086A1 (ru) 2000-06-26
SK158199A3 (en) 2000-06-12
EP1001946B1 (en) 2010-12-29
CZ296845B6 (cs) 2006-07-12
CN1280572A (zh) 2001-01-17
EP1001945B1 (en) 2011-03-02
EA004103B1 (ru) 2003-12-25
AU751188C (en) 2005-06-30
PL337086A1 (en) 2000-07-31
IL133007A0 (en) 2001-03-19
ATE500233T1 (de) 2011-03-15
KR20010039512A (ko) 2001-05-15
PL337084A1 (en) 2000-07-31
NO323721B1 (no) 2007-06-25
ATE286886T1 (de) 2005-01-15
AU751188B2 (en) 2002-08-08
DE69842151D1 (de) 2011-04-14
EP0991628A1 (en) 2000-04-12
BG64445B1 (en) 2005-02-28
AU7706298A (en) 1998-12-30
EP1001946A1 (en) 2000-05-24
UA57790C2 (uk) 2003-07-15
EP0991628A4 (en) 2000-07-26
SK286084B6 (sk) 2008-03-05
EA199901092A1 (ru) 2000-06-26
PL194980B1 (pl) 2007-07-31
NO995817L (no) 1999-11-26
DE69842077D1 (de) 2011-02-10
AU742739B2 (en) 2002-01-10
NO323720B1 (no) 2007-06-25
BG103965A (en) 2000-07-31
CZ417999A3 (cs) 2000-05-17
BG64444B1 (en) 2005-02-28
KR100425638B1 (ko) 2004-04-03
IL133009A0 (en) 2001-03-19
IL133008A0 (en) 2001-03-19
CA2291728A1 (en) 1998-12-03
BR9809501A (pt) 2000-06-20
BG103963A (en) 2000-07-31
EA199901090A1 (ru) 2000-08-28
DE69828607T2 (de) 2006-01-05
OA11264A (en) 2002-11-19
AP9901710A0 (en) 1999-12-31
AU7707998A (en) 1998-12-30
CZ415899A3 (cs) 2000-05-17
EP1001945A1 (en) 2000-05-24
CN1261353A (zh) 2000-07-26
JP2002513417A (ja) 2002-05-08
JP2002500675A (ja) 2002-01-08
NO316377B1 (no) 2004-01-19
CA2291750A1 (en) 1998-12-03
NO995819L (no) 1999-11-26
CZ298490B6 (cs) 2007-10-17
CA2291774A1 (en) 1998-12-03
PL194670B1 (pl) 2007-06-29
EA200100575A1 (ru) 2002-02-28
CZ418099A3 (cs) 2000-05-17
JP2002500676A (ja) 2002-01-08
BG64419B1 (bg) 2005-01-31
CN1140516C (zh) 2004-03-03
WO1998054156A1 (en) 1998-12-03
AP9901711A0 (en) 1999-12-31
ATE493389T1 (de) 2011-01-15
EA007807B1 (ru) 2007-02-27
SI0991628T1 (en) 2005-06-30
EP1001946A4 (en) 2000-07-26
CN1261354A (zh) 2000-07-26
AP9901709A0 (en) 1999-12-31
KR20010013057A (ko) 2001-02-26
PL337087A1 (en) 2000-07-31
BR9809515A (pt) 2000-06-20
DK0991628T3 (da) 2005-05-17
ES2235331T3 (es) 2005-07-01
AP1554A (en) 2006-01-18
OA11222A (en) 2003-07-16
IL133007A (en) 2005-06-19
PT991628E (pt) 2005-05-31
NO995818D0 (no) 1999-11-26
AU7803798A (en) 1998-12-30
BG104006A (en) 2000-07-31
EA002600B1 (ru) 2002-06-27
HUP0002084A2 (hu) 2000-10-28

Similar Documents

Publication Publication Date Title
OA11221A (en) Quinoline and quinoxaline compounds which inhibit platelet-derived growt factor and/or p561ck tyrosine kinases
US6482834B2 (en) Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6528526B1 (en) Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
MXPA99011025A (en) QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p561ck
MXPA99011017A (en) QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56lck
MXPA01005318A (en) Quinoline and quinoxaline compounds as pdgf-r and/or lck tyrosine kinase inhibitors